Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 02/03/24
End: 02/02/27
Due: 02/02/28
Phase: N/A
Priority: Normal
Start: 04/30/23
End: 03/31/26
Due: 03/31/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study | NCT06241469 | Wu Jun | user2@example.com | None | 2024-02-03 | 2027-02-02 | 2028-02-02 | - | - | 2025-07-14 |
| Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study | NCT05721651 | Wu Jun | user2@example.com | None | 2023-04-30 | 2026-03-31 | 2027-03-31 | - | - | 2025-07-14 |